Results 61 to 70 of about 38,078,382 (138)
Virtual institutions prototype
, 2009 Virtual Institutions are Virtual Worlds with normative regulation of participants’ interactions. This paradigm is based on normative multiagent systems and is technologically supported by Electronic Institutions.
Simoff, Simeon J. +2 more
core
Humane by design: Toward safe, human‐centered multi‐agent systems
AI Magazine, Volume 47, Issue 4, Winter 2026.Abstract Multi‐agent systems (MAS) are helping to unleash AI from the solitary confinement of standalone applications so they can perform coordinated actions in the wider world, functioning within distributed networks of people, tools, and other agents.
Jeffrey M. Bradshaw +5 more
wiley +1 more source
From “how” to learn to “what” to learn in multiagent systems and robotics
AI Magazine, Volume 47, Issue 4, Winter 2026.Abstract There remains much more to Artificial Intelligence than understanding how to learn with neural networks. Inspired in part by how babies, and humans in general, tend to choose for themselves what (and when) to learn in addition to how to learn, this article discusses similar opportunities, in the areas of multiagent systems and robotics ...
Peter Stone
wiley +1 more source
Decentralized bisimulation for multiagent systems [PDF]
, 2015 Copyright © 2015, International Foundation for Autonomous Agents and Multiagent Systems. The notion of bisimulation has been introduced as a powerful way to abstract from details of systems in the formal verification community.
Feng, Y, Zhang, L, Song, L
core
European Journal of Haematology, Volume 117, Issue 6, Page 1601-1611, December 2026.ABSTRACT Concerns about treatment‐related fertility impairment are common among young adult lymphoma survivors. Evidence on the impact of treatment for aggressive non‐Hodgkin lymphoma (NHL) on future childbearing is limited, although many individuals of reproductive age are affected.
Stefanie Antonilli +10 more
wiley +1 more source
Toxicity of Cytarabine Intravenous Constant Rate Infusion in Cats With Lymphoma
Veterinary and Comparative Oncology, Volume 24, Issue 4, Page 830-840, December 2026.ABSTRACT Cytarabine intravenous constant rate infusion (IV CRI) toxicity in cats with lymphoma has not been well documented. We aimed to assess toxicities following cytarabine IV CRI as a single‐agent or within a multiagent protocol in cats with lymphoma. Medical records of cats with lymphoma treated with cytarabine IV CRI, with documented dose, route,
Rachel Hanford +5 more
wiley +1 more source
ClinX‐Net: Multimodal Visual–Language Feature Fusion for Chest X‐Ray Report Generation
International Journal of Imaging Systems and Technology, Volume 36, Issue 6, November 2026.ABSTRACT Automated chest X‐ray report generation has the potential to improve reporting efficiency and reduce variability in radiological documentation. However, existing methods remain challenged by subtle abnormality description, long‐range textual consistency, and effective integration of clinical information with visual findings.
Muhammad Sufyan Khan +5 more
wiley +1 more source
MedComm, Volume 7, Issue 11, November 2026.This review summarizes current therapeutic and prophylactic strategies for global viral diseases, including vaccines, PrEP, direct‐acting antivirals, and emerging modalities such as CRISPR and siRNA. It highlights their clinical impact, ongoing challenges, and future priorities toward broader protection, improved delivery, and more effective antiviral ...
Sawar Khan +12 more
wiley +1 more source
Parameterized Algorithms for Multiagent Pathfinding on Trees
The classical Multiagent Pathfinding problem has been extensively studied not only within the artificial intelligence research community, but also by scholars in the areas of theoretical computer science and computational geometry. The problem asks for a
Ramanujan, M. S.; orcid: +4 more
core +1 more source
British Journal of Haematology, Volume 209, Issue 5, Page 2094-2102, November 2026.BrECADD can be delivered over 3 days instead of four, reducing intravenous treatment days by 25% without compromising dose intensity. Among 30 patients with advanced‐stage Hodgkin lymphoma, no unexpected toxicity was observed; there were no early discontinuations, and 1‐year progression‐free and overall survival were both 100%.
Christian Peter Jaworek +16 more
wiley +1 more source